

Administration of naloxone to doses of 4 mg subcutaneously did not precipitate any discernible abstinence as measured by the abstinence score or by subjects' reports of withdrawal illness (Fig. 17). These same doses will precipitate abstinence in subjects dependent upon 30 mg of morphine daily (7.5 mg q.i.d.) and in subjects receiving chronic pentazocine or chronic butorphanol (Fig. 17). After completion of the precipitation tests, the 3 subjects who did not withdraw were stabilized on buprenorphine for 8 more days and then saline placebo was substituted under double blind conditions.




Figure 17. Abstinence scores following the administration of placebo and naloxone to subjects dependent upon morphine, 30 mg daily (7.5 mg q.i.d.), buprenorphine, 8 mg, butorphanol, 48 mg daily (12 mg q.i.d.), and pentazocine, 580 mg daily.